Korean AI drug developer secures $14m Series B
Oncocross, a South Korean drug developer that uses artificial intelligence (AI) to identify new applications for treatments already in clinical trials, has raised KRW16.5 billion ($14 million) in Series B funding led by Smilegate Investment and GNTech Venture Capital.
The company is now in discussions with domestic and Chinese strategic investors regarding partnerships and additional investments prior to a KRW10-20 billion pre-IPO round, CEO Kim Yi-rang told Mergermarket....
More on North Asia
Latest News
Bertelsmann to invest $500m in India
Bertelsmann India Investments has earmarked USD 500m, provided by its eponymous German parent, for investment in local start-ups. The VC unit’s total deployment since its launch in 2013 is USD 285m.
Entrepreneur First raises $158m, targets SE Asia
UK-headquartered incubator Entrepreneur First (EF) has raised USD 158m, targeted in part at investment in Southeast Asian start-ups and expanding its reach in the region.
CDH exits New Zealand supplements brand to Nestle
CDH Investments has agreed to sell New Zealand-based supplements manufacturer The Better Health Company (TBHC) to Nestlé Health Science for an undisclosed sum.
Panthera hits first close on India, Southeast Asia fund
India and Southeast Asia-focused Panthera Growth Partners has reached a first close on its second fund with commitments amounting to more than half the overall target of USD 250m.